An overview of sipuleucel-T: autologous cellular immunotherapy for prostate cancer.

Abstract

Sipuleucel-T, the first autologous active cellular immunotherapy approved by the United States Food and Drug Administration, is designed to stimulate an immune response to prostate cancer. Sipuleucel-T is manufactured by culturing a patient's peripheral blood mononuclear cells (including antigen presenting cells) with a recombinant protein comprising a… (More)
DOI: 10.4161/hv.18769

Topics

Statistics

0102030201520162017
Citations per Year

Citation Velocity: 8

Averaging 8 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.
  • Presentations referencing similar topics